Abstract
Icotinib hydrochloride is a small epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) that was developed by Chinese scientists. While clinical trials have revealed its efficacy in the treatment of lung cancer, very little is known about its role in enhancing radiosensitivity. In this study, we investigated the effectiveness of Icotinib in enhancing lung cancer cell radiosensitivity and have detailed its underlying molecular mechanism. The lung cancer cell line H1650 was pretreated with or without Icotinib for 24 hours before radiation, and clonogenic survival assay was performed. Cell apoptosis was also analyzed by flow cytometry, while western blotting was performed to examine the activation of EGFR and its downstream kinases in H1650 cells after Icotinib and radiation treatment. Furthermore, a xenograft animal model was established to evaluate the radiosensitivity of Icotinib in vivo and to confirm its mechanism. Our results demonstrate that pretreatment with Icotinib reduced clonogenic survival after radiation, inhibited EGFR activation, and increased radiation-induced apoptosis in H1650 cells. The phosphorylation of protein kinase B (AKT), extracellular regulated protein kinase 1/2 (ERK1/2), and EGFR was i...Continue Reading
References
May 31, 2002·Oncogene·Joseph N ContessaRupert K Schmidt-Ullrich
Nov 30, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Barbara BurtnessUNKNOWN Eastern Cooperative Oncology Group
Feb 10, 2006·The New England Journal of Medicine·James A BonnerK Kian Ang
Jul 5, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Mahmoud ToulanyH Peter Rodemann
Nov 17, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·David J Chen, Chaitanya S Nirodi
Feb 7, 2008·British Journal of Cancer·Y AkashiK Nakagawa
Feb 22, 2008·Current Medicinal Chemistry·Howard B Lieberman
Dec 31, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Carsten BokemeyerPiotr Koralewski
May 13, 2009·Cancer Science·Hong-Qing ZhuangChang-Li Wang
Aug 27, 2009·Biologics : Targets & Therapy·Chad A Reade, Apar Kishor Ganti
Feb 20, 2010·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Marcel VerheijBaukelien van Triest
Oct 6, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jean-Yves DouillardJennifer Gansert
Jan 26, 2011·Cancer·Alexandra D JensenKlaus K Herfarth
May 11, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·George R BlumenscheinRitsuko Komaki
Nov 25, 2011·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Fenlai TanYinxiang Wang
May 28, 2013·The Cancer Journal·Henning WillersFen Xia
Dec 19, 2013·Genes & Cancer·Anupama Munshi, Rajagopal Ramesh
May 20, 2014·PloS One·Xiaofeng ChenLingjun Zhu
Apr 22, 2015·International Journal of Radiation Oncology, Biology, Physics·Stamatia E PouliliouMichael I Koukourakis
May 9, 2015·Frontiers in Genetics·Alessandro Torgovnick, Björn Schumacher
Jun 20, 2015·Current Oncology·P M EllisY C Ung
Jun 3, 2016·PloS One·Corina PenterlingAnna A Friedl
Oct 8, 2016·Oncotarget·Hongqing ZhuangPing Wang
Citations
Jul 6, 2018·Biomedical Chromatography : BMC·Ying XiaoLi Chen
Dec 15, 2018·Molecular Oncology·Cornelia BraicuIoana Berindan-Neagoe
Feb 1, 2020·Journal of Translational Medicine·Menglei LiTong Tong
Jun 13, 2019·BioMed Research International·Lunfei LiuZourong Ruan
Oct 27, 2020·Frontiers in Pharmacology·Long-Fei MaoYue-Ming Li
Apr 15, 2021·Clinical Lung Cancer·Jeong Uk Lim
Aug 11, 2021·Phytotherapy Research : PTR·Meng JinSen Zhang